Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BMS-663068 Formulations in Healthy Subjects
NCT02859259Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Relative Bioavailability of BMS-626529 at 8 days. Started Aug 2016; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02859259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859259.